Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 13Colorectal Neoplasms 10Carcinoma, Merkel Cell 9Breast Neoplasms 9Carcinoma, Renal Cell 7Neoplasms 6Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 6Small Cell Lung Carcinoma 4Carcinoma, Hepatocellular 4Turcot syndrome 3Stomach Neoplasms 3Neuroendocrine Tumors 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Penile Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2Lung Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Neuroendocrine 2Uterine Cervical Neoplasms 1

Interventions

Fulvestrant 3Alpelisib 3parsaclisib 2Paclitaxel 2Irinotecan 2Cetuximab 2Carboplatin 2tanezumab 1talazoparib 1sotorasib 1serabelisib 1sapanisertib 1ruxolitinib 1olaparib 1niraparib 1liposomal doxorubicin 1inavolisib 1dapagliflozin 1ceralasertib 1binimetinib 1berzosertib 1avelumab 1Vemurafenib 1Topotecan 1Taxes 1SF 1126 1Oxaliplatin 1Lomustine 1Leuprolide 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Sensory and Autonomic Neuropathies × avelumab × Clear all
NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Pfizer

Phase 2 Terminated
202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡